Urovant Sciences Ltd.
UROV evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Lead Asset:
- uro-902 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for UROV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
uro-902 (Phase 2)
Next Catalyst
—
Tracking 1 pipeline candidate · 1 clinical trial for Urovant Sciences Ltd..
Similar companies
Run Urovant Sciences Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Urovant Sciences Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Urovant Sciences Ltd.'s lead drug candidate?
Urovant Sciences Ltd.'s most advanced tracked candidate is uro-902 (Phase 2) for overactive bladder (OAB) in patients who have failed oral pharmacological therapy.
Who is the CEO of Urovant Sciences Ltd.?
Sumitovant Biopharma Inc is the chief executive officer of Urovant Sciences Ltd. (UROV).
What therapeutic areas does Urovant Sciences Ltd. focus on?
Urovant Sciences Ltd. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.